New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
08:41 EDTFINL, FL, LULU, LLY, AUO, FOLD, SONC, ARAYOn The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse.
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days
Check below for free stories on FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 22, 2014
09:05 EDTFLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: GameStop (GME), up 7.1%... Foot Locker (FL), up 3%... Qunar (QUNR), up 6.9%... The Fresh Market (TFM), up 6.5%... Ross Stores (ROST), up 3.8%. ALSO HIGHER: El Pollo Loco (LOCO), up 5.3% after signing franchisee to 20 unit expansion agreement in Texas... Gap (GPS), up 2.8% after upgraded at Janney Capital following Q2 results above analyst estimates and announcing plans to open the first franchise-operated Gap stores in India in 2015. DOWN AFTER EARNINGS: Aeropostale (ARO), down 8%... Ann Inc (ANN), down 2.7%. ALSO LOWER: Ampio (AMPE), down 4.4% after downgraded at Jefferies...
07:01 EDTFLFoot Locker reports Q2 SSS up 7%
Reports Q2 gross margin rate up to 32%
07:01 EDTFLFoot Locker reports Q2 adjusted EPS 64c, consensus 54c
Subscribe for More Information
August 21, 2014
16:13 EDTARAYAccuray sees FY14 revenue $390M-$410M, consensus 359.52M
Subscribe for More Information
16:11 EDTARAYAccuray reports Q4 EPS (13c), consensus (7c)
Subscribe for More Information
15:15 EDTFLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Foot Locker (FL), consensus 54c; ANN INC. (ANN), consensus 68c; Hibbett Sports (HIBB), consensus 31c.
10:22 EDTFOLDOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD VHC ACHN JCP WB JD YPF
07:51 EDTFLFoot Locker price target raised to $58 from $54 at UBS
UBS raised its price target on Foot Locker to $58 from $54 ahead of Q2 results. The firm sees higher than expected earnings, positive same store sales trends, potential for increased guidance, and valuation. Shares of foot Locker are buy rated.
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
06:58 EDTAUOLarge-size panel demand increases in Q2 with LG Display in lead, DigiTimes says
Subscribe for More Information
August 20, 2014
11:42 EDTFOLDOptions with decreasing implied volatility
Subscribe for More Information
11:09 EDTFOLDHigh option volume stocks
Subscribe for More Information
10:31 EDTFOLDAmicus price target raised its price target to $14 from $9 at Cowen
Subscribe for More Information
09:36 EDTFOLDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FOLD TSLA TWTR WHX FB TM NFLX X EOG
09:07 EDTFOLDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PetSmart (PETM), up 2,1%... Staples (SPLS), up 2%... E-House (EJ), up 2.5%. HIGHER: Fairchild (FCS), up 4% after Bloomberg says Infineon (IFNNY) is near a deal to buy a U.S. semiconductor company for $2B... Amicus Therapeutics (FOLD), up 18.4% after reporting positive Phase 3 data from the Fabry study. DOWN AFTER EARNINGS: Lowe's (LOW), down 3%... Tarena (TEDU), down 9%... Leju (LEJU), down 4.2%... JA Solar (JASO), down 5%. LOWER: Hertz (HTZ), down 12.7% after downgraded at JPMorgan and Deutsche Bank following the company's decision to withdraw its FY14 guidance... NovaBay (NBY), down 35.2% after primary, secondary endpoints were not met in its NVC-422 study... RGS Energy (RGSE), down 14.9% after downgraded at Roth Capital following Q2 earnings results.
08:00 EDTFLFoot Locker Q2 results expected to be solid, says Canaccord
Canaccord said they are positive on Foot Locker heading into Q2 results as they expect results to be solid. The firm feels Foot Locker is well positioned to continue benefiting from the expanding tend toward casual athletic footwear. Shares of Foot Locker are buy rated with a $56 price target.
06:34 EDTFOLDAmicus Therapeutics to host conference call
Conference call to discuss results of Phase 3 Fabry monotherapy study will be held on August 20 at 8 am. Webcast Link
06:08 EDTFOLDAmicus Therapeutics reports positive Phase 3 data from Fabry study
Subscribe for More Information
August 19, 2014
13:40 EDTFLFoot Locker September volatility up into Q2 and guidance
Subscribe for More Information
13:38 EDTFLFoot Locker same-store-sales tracking above consensus, says ITG Research
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use